BRPI0417769B8 - método sintético para a aquilação redutiva na posição c-3 de indóis - Google Patents

método sintético para a aquilação redutiva na posição c-3 de indóis

Info

Publication number
BRPI0417769B8
BRPI0417769B8 BRPI0417769A BRPI0417769A BRPI0417769B8 BR PI0417769 B8 BRPI0417769 B8 BR PI0417769B8 BR PI0417769 A BRPI0417769 A BR PI0417769A BR PI0417769 A BRPI0417769 A BR PI0417769A BR PI0417769 B8 BRPI0417769 B8 BR PI0417769B8
Authority
BR
Brazil
Prior art keywords
indoles
reductive alkylation
synthetic method
alkylation
indole
Prior art date
Application number
BRPI0417769A
Other languages
English (en)
Inventor
Raveendranath Panolil
S Michalak Ronald
Original Assignee
Wyeth Corp
Wyeth Llc
Ziarco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Wyeth Llc, Ziarco Inc filed Critical Wyeth Corp
Publication of BRPI0417769A publication Critical patent/BRPI0417769A/pt
Publication of BRPI0417769A8 publication Critical patent/BRPI0417769A8/pt
Publication of BRPI0417769B1 publication Critical patent/BRPI0417769B1/pt
Publication of BRPI0417769B8 publication Critical patent/BRPI0417769B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

metodologia sintética para a aquilação redutiva na posição c-3 de indóis. a presente invenção refere-se a um processo para a alquilação redutiva na posição c-3 de um composto de indol em que o indol é tratado com um aldeído na presença de um ácido de lewis e um agente de redução de hidreto de silício. o processo é útil para a alquilação na posição c-3 dos indóis que contêm substituintes sensíveis a ácido na posição n-1.
BRPI0417769A 2003-12-16 2004-12-15 método sintético para a aquilação redutiva na posição c-3 de indóis BRPI0417769B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52979703P 2003-12-16 2003-12-16
PCT/US2004/041989 WO2005058820A1 (en) 2003-12-16 2004-12-15 A synthetic methodology for the reductive alkylation at the c-3 position of indoles
US11/014,657 US7282594B2 (en) 2003-12-16 2004-12-16 Synthetic methodology for the reductive alkylation at the C-3 position of indoles

Publications (4)

Publication Number Publication Date
BRPI0417769A BRPI0417769A (pt) 2007-04-17
BRPI0417769A8 BRPI0417769A8 (pt) 2018-05-08
BRPI0417769B1 BRPI0417769B1 (pt) 2019-12-17
BRPI0417769B8 true BRPI0417769B8 (pt) 2021-05-25

Family

ID=34700047

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417769A BRPI0417769B8 (pt) 2003-12-16 2004-12-15 método sintético para a aquilação redutiva na posição c-3 de indóis

Country Status (26)

Country Link
US (2) US7282594B2 (pt)
EP (1) EP1697320B1 (pt)
JP (1) JP5121232B2 (pt)
KR (2) KR20120082477A (pt)
CN (1) CN1914170B (pt)
AR (1) AR046895A1 (pt)
AU (1) AU2004299462B2 (pt)
BR (1) BRPI0417769B8 (pt)
CA (1) CA2549120C (pt)
CR (1) CR8446A (pt)
EC (1) ECSP066648A (pt)
EG (1) EG24473A (pt)
GT (1) GT200400266A (pt)
HN (1) HN2004000536A (pt)
IL (1) IL176147A (pt)
MX (1) MXPA06006669A (pt)
NI (1) NI200600132A (pt)
NO (1) NO20062757L (pt)
PA (1) PA8620101A1 (pt)
PE (1) PE20051012A1 (pt)
RU (1) RU2352560C2 (pt)
SG (1) SG147487A1 (pt)
TW (1) TW200526576A (pt)
UA (1) UA84445C2 (pt)
WO (1) WO2005058820A1 (pt)
ZA (1) ZA200604966B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
TW200510305A (en) 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7582771B2 (en) * 2003-09-03 2009-09-01 Wyeth Process for the synthesis of cPLA2 inhibitors
US7342119B2 (en) * 2003-09-30 2008-03-11 Wyeth Holdings Corporation Process for the synthesis of a CPLA2 inhibitor
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
GT200600228A (es) * 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
TW200826932A (en) * 2006-10-31 2008-07-01 Wyeth Corp Semi-solid formulations of phospholipase enzyme inhibitors
EP2104498A2 (en) * 2006-10-31 2009-09-30 Wyeth Liquid formulations of phospholipase enzyme inhibitors
CN111087340B (zh) * 2019-11-29 2021-12-07 上海应用技术大学 一种维拉佐酮中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
GB9609641D0 (en) * 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
TWI334778B (en) * 2001-12-03 2010-12-21 Wyeth Corp Inhibitors of cytosolic phospholipase a2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US20040182785A1 (en) * 2002-10-23 2004-09-23 Rigel Technology Corporation Animal plasma process by precipitation
TW200510305A (en) 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7582771B2 (en) 2003-09-03 2009-09-01 Wyeth Process for the synthesis of cPLA2 inhibitors
US7342119B2 (en) * 2003-09-30 2008-03-11 Wyeth Holdings Corporation Process for the synthesis of a CPLA2 inhibitor
AR053410A1 (es) 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
GT200600228A (es) 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica

Also Published As

Publication number Publication date
US7709661B2 (en) 2010-05-04
PE20051012A1 (es) 2006-01-13
CR8446A (es) 2006-12-07
JP2007514004A (ja) 2007-05-31
JP5121232B2 (ja) 2013-01-16
EP1697320B1 (en) 2013-04-10
EP1697320A1 (en) 2006-09-06
KR20120082477A (ko) 2012-07-23
TW200526576A (en) 2005-08-16
KR20070018820A (ko) 2007-02-14
BRPI0417769A (pt) 2007-04-17
BRPI0417769B1 (pt) 2019-12-17
EG24473A (en) 2009-08-03
KR101194592B1 (ko) 2012-10-25
AU2004299462B2 (en) 2011-07-14
IL176147A0 (en) 2006-10-05
US20050148770A1 (en) 2005-07-07
NI200600132A (es) 2007-01-17
MXPA06006669A (es) 2006-08-11
RU2352560C2 (ru) 2009-04-20
UA84445C2 (ru) 2008-10-27
CN1914170A (zh) 2007-02-14
AU2004299462A1 (en) 2005-06-30
BRPI0417769A8 (pt) 2018-05-08
ECSP066648A (es) 2006-10-25
CA2549120C (en) 2012-06-26
CA2549120A1 (en) 2005-06-30
NO20062757L (no) 2006-06-28
SG147487A1 (en) 2008-11-28
GT200400266A (es) 2005-08-30
US20080161581A1 (en) 2008-07-03
PA8620101A1 (es) 2006-03-24
RU2006125447A (ru) 2008-01-27
WO2005058820A1 (en) 2005-06-30
CN1914170B (zh) 2010-07-14
US7282594B2 (en) 2007-10-16
ZA200604966B (en) 2010-11-24
IL176147A (en) 2011-12-29
HN2004000536A (es) 2009-02-18
AR046895A1 (es) 2005-12-28

Similar Documents

Publication Publication Date Title
ECSP066648A (es) Metodologia sintetica para la alquilacion reductiva en la posicion c-3 de indoles
BRPI0606524A2 (pt) derivados de indol para o tratamento de infecções virais
DE60211245D1 (de) Anordnungsstruktur einer Diebstahlsicherung für Motorräder
BR9910029A (pt) Hidróxi indóis, sua aplicação como inibidores da fosfodiesterase 4 e processo para sua preparação
ATE392206T1 (de) Indolderivate als beta-2 agonisten
BR0212925A (pt) Derivados de idol como inibidores de cox ii
EA200702510A1 (ru) Способы защиты от апоптоза с применением липопептидов
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
AR030893A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gabaa para el tratamiento de trastornos cognitivos
CO5780132A1 (es) Nueva forma cristalina y de la agomelatina, suprocedimiento de preparacion y las composiciones que las contienen
PE20050088A1 (es) Proceso para la fabricacion de valsartan
ITTO20030718A1 (it) Dispositivo antifurto per motocicli
DE60323875D1 (de) Eine atp-rückzykluslänge verwendende vorrichtung zur unterscheidung von arrythmien
SG148215A1 (en) Methods of protecting against radiation using flagellin
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
MX2007015130A (es) Nuevos derivados de pirroliltriazina asi como procedimientos para su obtencion y su utilizacion como agentes protectores contra la radiacion uv.
PE20040928A1 (es) Derivados de tetrahidroquinolinas como moduladores del receptor fsh
BRPI0412904A (pt) processo para a preparação de inibidores de cpla2
BR0107978A (pt) Cera de vela estabilizada por uma combinação de absorvente de radiação uv mais uma amina impedida selecionada
EA201100350A1 (ru) Противогрибковые средства
AR056805A1 (es) Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
ECSP034760A (es) Inhibidores de la captacion de monoamina
BR9914780A (pt) Processo de preparação de um composto defórmula (i) e composto produzido através de talprocesso
BRPI0411957A (pt) método para diminuir o teor de aldeìdo de poliésteres
BRPI0417595A (pt) dispositivo de sebe protetora vegetal e processo de realização do referido dispositivo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: WYETH (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20130073204/RJ DE 30/08/2013, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DO TITULAR DO PEDIDO E O NOME DA EMPRESA QUE CONSTA NO DOCUMENTO DE CESSAO.

B25D Requested change of name of applicant approved

Owner name: WYETH LLC (US)

B25A Requested transfer of rights approved

Owner name: ZIARCO INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.